Journal
JOURNAL OF NEUROCHEMISTRY
Volume 157, Issue 2, Pages 165-178Publisher
WILEY
DOI: 10.1111/jnc.15120
Keywords
encephalopathy; epilepsy; Munc18-1; STXBP1; synapse; therapeutic approaches
Categories
Funding
- Weill Cornell/Rockefeller/Sloan Kettering Tri-Institutional MD PhD Program [T32GM007739]
- National Institute of Neurological Disorders and Stroke [R01-NS102181, R01-NS113960]
Ask authors/readers for more resources
Mutations in the STXBP1 gene can lead to severe early epileptic encephalopathies and neurodevelopmental disorders, with no identified genotype-phenotype correlation. Current therapy involves anti-epileptic drugs, and the disease mechanisms may involve haploinsufficiency and dominant-negative effects.
Mutations in Munc18-1/STXBP1 (syntaxin-binding protein 1) are linked to various severe early epileptic encephalopathies and neurodevelopmental disorders. Heterozygous mutations in the STXBP1 gene include missense, nonsense, frameshift, and splice site mutations, as well as intragenic deletions and duplications and whole-gene deletions. No genotype-phenotype correlation has been identified so far, and patients are treated by anti-epileptic drugs because of the lack of a specific disease-modifying therapy. The molecular disease mechanisms underlying STXBP1-linked disorders are yet to be fully understood, but both haploinsufficiency and dominant-negative mechanisms have been proposed. This review focuses on the current understanding of the phenotypic spectrum of STXBP1-linked disorders, as well as discusses disease mechanisms in the context of the numerous pathways in which STXBP1 functions in the brain. We additionally evaluate the available animal models to study these disorders and highlight potential therapeutic approaches for treating these devastating diseases.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available